NRX Pharmaceuticals, Inc.

Big Rock Partners Acquisition Corp, listed on Nasdaq under the ticker BRPA and sponsored by Big Rock Partners LLC, completed its IPO in 2018 with a focus on the healthcare and life sciences sector. The entity filed a 10-Q with the SEC on August 14, 2020, under the registrant name NRX Pharmaceuticals, Inc., reflecting the announced business combination with the clinical-stage biopharmaceutical company developing treatments for neurological and pulmonary conditions. The de-SPAC transaction ultimately closed, transitioning BRPA from blank-check status to an operating public company in the pharmaceutical space. Investors and analysts seeking full filing history, deal timelines, and SPAC analytics on BRPA can sign up for complete data access at SpacDesk.